Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $65,800.00 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 658 shares of Mirum Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total transaction of $65,800.00. Following the completion of the transaction, the senior vice president directly owned 616 shares of the company’s stock, valued at $61,600. This trade represents a 51.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe also recently made the following trade(s):

• On Tuesday, August 18th, Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00.
• On Monday, August 3rd, Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $105.29, for a total value of $193,733.60.
• On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $120.00, for a total value of $326,520.00.
• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $101.95, for a total value of $264,458.30.

Mirum Pharmaceuticals Stock Up 0.3%

Shares of Mirum Pharmaceuticals stock opened at $100.90 on Friday. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28. The business’s 50 day simple moving average is $109.09 and its 200-day simple moving average is $101.73. The stock has a market capitalization of $6.55 billion, a price-to-earnings ratio of -6.93 and a beta of 0.49. Mirum Pharmaceuticals, Inc. has a twelve month low of $63.23 and a twelve month high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The company had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The company’s revenue for the quarter was up 37.9% on a year-over-year basis. During the same period last year, the business posted ($0.12) EPS. Equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Janus Henderson Group PLC raised its position in shares of Mirum Pharmaceuticals by 14.5% during the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after buying an additional 880,505 shares in the last quarter. Jupiter Topco LLC bought a new position in shares of Mirum Pharmaceuticals in the second quarter valued at approximately $691,672,000. California State Teachers Retirement System boosted its holdings in shares of Mirum Pharmaceuticals by 12,542.7% in the second quarter. California State Teachers Retirement System now owns 5,622,989 shares of the company’s stock valued at $658,283,000 after acquiring an additional 5,578,513 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Mirum Pharmaceuticals during the second quarter valued at approximately $513,945,000. Finally, Vanguard Group Inc. increased its stake in shares of Mirum Pharmaceuticals by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock valued at $205,065,000 after acquiring an additional 50,720 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Wall Street Zen lowered shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday. Citizens Jmp restated a “market outperform” rating and issued a $137.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. HC Wainwright cut their price target on Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Royal Bank Of Canada decreased their price objective on Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Finally, Wolfe Research began coverage on Mirum Pharmaceuticals in a research report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $137.31.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.